Clinical Trial

Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

Study acronym: CHESS
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy plus stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the locoregional primary tumour, in patients with histologically-confirmed synchronous oligo-metastatic non-small cell lung cancer (NSCLC).
Protocol Amendment History 27 amendments
This ClinicalTrials.gov record has been amended 27 times since 2019-05-28; most recent amendment 2026-02-05.
Status change: Recruiting → Active, Not Recruiting 2026-02-05
Status change: Active, Not Recruiting → Recruiting 2023-08-29
Status change: Recruiting → Active, Not Recruiting 2022-08-23
Status change: Not Yet Recruiting → Recruiting 2019-11-27
Trial Details
NCT Number NCT03965468
Lead Sponsor ETOP IBCSG Partners Foundation
Collaborators: AstraZeneca
Conditions Non-small Cell Lung Cancer, Stage IV, Oligometastasis
Enrollment 96 participants
Start Date 2019-11-19
Primary Completion 2026-08 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-09